Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maze Therapeutics (MAZE) Net Margin (2024 - 2026)

Maze Therapeutics' Net Margin history spans 2 years, with the latest figure at 121.04% for Q1 2026.

  • On a quarterly basis, Net Margin changed N/A to 121.04% in Q1 2026 year-over-year; TTM through Mar 2026 was 612.71%, a N/A change, with the full-year FY2024 number at 22.7%, changed N/A from a year prior.
  • Net Margin hit 121.04% in Q1 2026 for Maze Therapeutics, down from 3.69% in the prior quarter.
  • Over the last five years, Net Margin for MAZE hit a ceiling of 9.26% in Q2 2024 and a floor of 990.08% in Q3 2024.